Cogent Biosciences, Inc. Segments Disclosure
13. Segment Information
The Company manages its operations as a operating segment for the purposes of assessing performance and making operating decisions. The Company’s singular focus is the development and commercialization of precision therapies for genetically defined diseases. Cogent’s chief operating decision maker (“CODM”) is the . The CODM manages and allocates resources to the operations of the Company on a total company basis and segment performance is evaluated based on consolidated net loss. The Company’s CEO uses consolidated financial information for purposes of evaluating performance, understanding future forecasted results and allocating resources. The measure of segment assets is reported on the balance sheet as total consolidated assets. All of the Company’s tangible assets are held in the United States.
The accounting policies for each operating segment are consistent with the Company’s policies for the consolidated financial statements.
The following table is a summary of segment information for the years ended December 31, 2025, 2024, 2023 (in thousands):
|
|
Year Ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Operating Expenses |
|
|
|
|
|
|
|
|
|
|||
Late-stage development |
|
$ |
120,059 |
|
|
$ |
120,862 |
|
|
$ |
85,484 |
|
Early-stage, preclinical and discovery programs |
|
|
40,112 |
|
|
|
28,141 |
|
|
|
19,171 |
|
R&D personnel related |
|
|
64,035 |
|
|
|
47,048 |
|
|
|
38,206 |
|
Research and development software, facilities and other strategic support |
|
|
20,085 |
|
|
|
10,812 |
|
|
|
9,374 |
|
Other operational infrastructure and advisory support |
|
|
40,429 |
|
|
|
26,886 |
|
|
|
23,010 |
|
Stock-based compensation expense |
|
|
46,079 |
|
|
|
39,740 |
|
|
|
30,621 |
|
Depreciation expense |
|
|
2,564 |
|
|
|
2,450 |
|
|
|
2,264 |
|
Interest income |
|
|
(14,689 |
) |
|
|
(18,088 |
) |
|
|
(13,077 |
) |
Interest expense |
|
|
3,062 |
|
|
|
— |
|
|
|
— |
|
Loss on debt extinguishment |
|
|
7,181 |
|
|
|
— |
|
|
|
— |
|
Change in fair value of CVR liability |
|
|
— |
|
|
|
— |
|
|
|
(1,700 |
) |
Other expense (income), net |
|
|
20 |
|
|
|
(1,992 |
) |
|
|
(943 |
) |
Segment net loss and consolidated net loss |
|
$ |
328,937 |
|
|
$ |
255,859 |
|
|
$ |
192,410 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 17, 2026 | Showing above |
| 2024 | Feb 25, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.